**Ex vivo PHA-induced IFN production** (pg/ml/5x10^5 CD4+ T cells)

- N / P infection: N = 6
- No N / P infection: N = 16
- Healthy controls: N = 8

Day 1-2: 10000
Day 7: 1000

**Ex vivo PHA-induced IL-2 production** (pg/ml/5x10^5 CD4+ T cells)

- N / P infection: N = 6
- No N / P infection: N = 16
- Healthy controls: N = 8

Day 1-2: 100
Day 7: 10

**Ex vivo PHA-induced IL-4 production** (pg/ml/5x10^5 CD4+ T cells)

- N / P infection: N = 6
- No N / P infection: N = 16
- Healthy controls: N = 8

Day 1-2: 0.1
Day 7: 0.1

**Ex vivo PHA-induced IL-10 production** (pg/ml/5x10^5 CD4+ T cells)

- N / P infection: N = 6
- No N / P infection: N = 16
- Healthy controls: N = 8

Day 1-2: 10
Day 7: 10

**Ex vivo PHA-induced IL-10 production** (pg/ml/5x10^5 CD4+ T cells)

- New or persistent infection: N = 6
- No new or persistent infection: N = 9

p = 0.06; ANOVA

**Ex vivo PHA-induced IL-4 production** (pg/ml/5x10^5 CD4+ T cells)

- New or persistent infection: N = 6
- No new or persistent infection: N = 9

p = 0.049; ANOVA

**Ex vivo PHA-induced IL-10 production** (pg/ml/5x10^5 CD4+ T cells)

- New or persistent infection: N = 6
- No new or persistent infection: N = 9

p = 0.4; ANOVA